Fecal steroid excretion of rats fed rice bran oil and oryzanol by Dai, Zhaoli
Louisiana State University
LSU Digital Commons
LSU Master's Theses Graduate School
2004
Fecal steroid excretion of rats fed rice bran oil and
oryzanol
Zhaoli Dai
Louisiana State University and Agricultural and Mechanical College
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses
Part of the Life Sciences Commons
This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU
Master's Theses by an authorized graduate school editor of LSU Digital Commons. For more information, please contact gradetd@lsu.edu.
Recommended Citation








FECAL STEROID EXCRETION OF RATS  














Submitted to the Graduate Faculty of the  
Louisiana State University and 
 Agricultural and Mechanical College 
 in partial fulfillment of the 
 requirements for the degree of  















 Zhaoli Dai 




 I would like to express my sincere appreciation to Dr. J. Samuel Godber, my 
major professor, who supported me and offered me such a great learning opportunity in 
this research.  His intelligence, academic perspectives and concern for his students 
impressed me greatly. My deep gratitude also goes to Dr. Zhimin Xu, who guided me 
throughout this project, from the basics, to method development, to advanced 
instrumentation and most important of all, his understanding and numerous 
encouragements throughout my graduate study and life during the past two years.  I also 
want to thank Dr. Maren Hegsted for serving as my committee member. Without her 
help, my graduate study on nutrition would not have gone as smoothly as I had hoped.  
 A special appreciation goes to a special friend, Brian Berger. His unending 
support and encouragement are unforgettable, especially during those hard times. Thanks 
are also extended for the help and advice from Michelle Smith Gillespie, Jean Huang, 
Ting Zhang and Heejoung An during this project.  
 Finally, my deepest appreciation goes to my family. Without their selfless 








TABLE OF CONTENTS 
ACKNOWLEDGEMENTS……………………………………………………………….ii 
LIST OF TABLES………………………………………………………………………...v 







2.1 NUTRITIONAL PROFILE OF RBO…………………………………………6  
 2.2 RICE BRAN OIL AND ITS EFFECTIVE COMPONENTS…………………8 
  2.2.1 Fatty Acids…………………………...…………………………...…8 
  2.2.2 Unsaponifiable Fractions (UF)…………………………………….10 
   2.2.2.1 Plant Sterols (Phytosterol)...……………………………..12 
   2.2.2.2 γ-Oryzanol………………………………………………..16 
   2.2.2.3 Tocopherols and Tocotrienols….………………………...19 
 2.3 POSSIBLE MECHANISMS OF CHOLESTEROL- 
                  LOWERING EFFECTS OF RBO..………………..………………………...22 
  2.3.1 Antioxidant Activity of Oryzanol and Tocotrienols in RBO………23 
 2.4 FECAL STEROID EXCRETION RELATED  
      TO CHOLESTEROL LEVEL ……………………....………………………24 
  2.4.1 Studies of Functional Foods Related to Fecal Steroid  
         Excretion and Cholesterol-lowering Effects..………...……………24 




 3.1 ANIMAL MODELS…………………………………………………………31 
 3.2 DIETS………………………………………………………………………..31 
 3.3 COLLECTION AND PREPARATION OF FECES………………………...33 
 3.4 EXTRACTION OF FECAL STEROIDS……………………………………33 
  3.4.1. Fecal Neutral Sterol Extraction and Analysis……………………..34 
  3.4.2. Fecal Bile Acid Extraction and Analysis………………………….35 
 3.5 OPTIMIZATION OF ANALYTICAL CONDITIONS …………………….37 
 3.6 FECAL ORYZANOL RECOVERY………………………………………...38 
3.7 GEL FORMING……………………………………………………………..38 
3.8 STATISTICAL ANALYSIS………………………………………………...38 
 
CHAPTER 4 
RESULTS AND DISCUSSION…………………………………………………………40 
 iv
4.1 COMPARISON OF DIFFERENCES BETWEEN TWO FECAL  
      COLLECTION PERIODS……………..…………………………………….40 
 4.2 CHOLESTEROL EXCRETION…………………………………………….40 
 4.3 FECAL ORYZANOL EXCRETION AMONG THE  
      TREATMENT GROUPS……………………..……………………………..43 
 4.4 FECAL BILE ACID EXCRETION…………………………………………46 
  4.4.1 Primary Bile Acids…………………….……..…………………….46 
  4.4.2 Secondary Bile Acids………………….…………..……………….48 
  4.4.3 Total Bile Acids………………………..…………………………..49 
 4.5 FECAL CHOLESTEROL VERSUS FECAL BILE ACIDS………………..52 
 4.6 OVARECTOMIZED RATS AND SHAM OPERATED RATS IN THE  
      CONTROL GROUPS…………..……………………………………………53 
4.7 FECAL BILE ACID EXTRACTION METHODS AND  
      DETERMINATION……………………..…………………………………..53 
 4.8 CHOLESTEROL-LOWERING EFFECTS OF ORYZANOL  
      AND PHYTOSTEROL……………..……………………………………….55 
 4.9 EFFECTS OF RICE BRAN OIL AND CORN OIL………………………...57 
 4.10 LIMITATIONS OF THIS STUDY………………………………………...58 
 
CHAPTER 5 
SUMMARY AND CONCLUSION………………………...………………….………..61 




APPENDIX A. 0.25 M SODIUM ACETATE BUFFER (PH5.6) SOLUTION…...……70 
 













LIST OF TABLES 
Table 1. Composition of Crude Rice Bran Oil………………..…………………………..7 
Table 2. Fatty Acid Composition of Rice Bran Oil and Peanut Oil……………………....9 
Table 3. Fatty Acid Composition of Rice Bran Oil and Corn Oil………………………...9 
Table 4. Diets Formula…………………………………………………………………..32 
Table 5. Comparison of Fecal Steroids between Collection Periods of A and B………..41 
Table 6. Effects of the Diets on Fecal Cholesterol Excretion……………………………42 
Table 7. Fecal Oryzanol Excretion among Three Treatment Groups…………………....44 
Table 8. Effects of the Diets on Fecal Primary Bile Acid Excretion…………………….47 
Table 9. Effects of the Diets on Fecal Secondary Bile Acid Excretion………………….48 













LIST OF FIGURES 
Figure 1. Chemical Structures of Cholesterol and Major Plant Sterols………………….13 
Figure 2. Three Major Components of γ-Oryzanol……………………………………...17 
Figure 3. Molecular Formulas of Tocopherols and Tocotrienols………………………..20 
Figure 4. Brief Biochemical Pathway of Conversion of  
   Cholesterol to Bile Salts and Sterols.…………………………………………..25 
  
Figure 5. Chemical Structures of Major Neutral Sterols…...…………………………....26 
 
Figure 6. Brief Pathway of Synthesis of Primary and Secondary Bile Acids…………....28 
Figure 7. Comparison of Primary Bile Acid Excretion among Treatment Groups……...51 


























 Rice bran oil (RBO) has been considered healthy cooking oil with potent effects 
to reduce the risks of atherosclerosis and coronary heart disease. The relatively high level 
of unsaponifiable components contributes to the healthy benefits of RBO.  This study 
investigated the possibility that the cholesterol-lowering effects of oryzanol are through 
increased fecal steroid excretion. The objective was to compare fecal cholesterol and bile 
acid excretion as well as bioavailability among different forms of oryzanol. The 
correlation between bioactivity and bioavailability of oryzanol was investigated as well. 
 Forty-seven female breeder rats were used as animal models. Oryzanol was added 
to an AIN-93 M maintenance diet at 2.8g/kg as the treatments. Treatments were either 
oryzanol in RBO, dissolved oil form of oryzanol in corn oil, or crystalline form of 
oryzanol added directly to the diet.  Control was corn oil. Fecal samples were collected at 
week 6 and 10.  Fecal cholesterol, oryzanol, and bile acids were analyzed with GC-FID.  
Results showed no significant differences between the two collection periods 
(P>0.05). Oryzanol in RBO produced the greatest fecal cholesterol excretion among the 
diet groups (P<0.05).  Both fecal cholesterol and total bile acid excretion were 
significantly higher in rats fed RBO oryzanol than the average of the other two treatment 
groups (P<0.001).  It may indicate that the hypocholesterolemic activity of RBO with 
oryzanol was more effective than oryzanol in corn oil, through synergistic effects of the 
components in the unsaponifiable contents. The possible mechanism for RBO and 
oryzanol to lower cholesterol levels appeared to be through inhibiting cholesterol 
absorption and bile acid reabsorption to enhance fecal cholesterol and bile acid excretion.   
 viii
 The effect of treatment compared to control was greater for bile acid excretion 
than for cholesterol excretion, which may suggest the primary mechanism of the 
hypocholesterolemic effect of oryzanol may be through the interference of bile acid 
reabsorption in the enterohepatic circulation.    
The correlation among different forms of oryzanol to the bioactivity was unclear, 
although the results showed fecal recovery of oryzanol was positively related to fecal 
steroid excretion. It might indicate the absorbability of oryzanol was negatively related to 
fecal steroid excretion. 
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CHAPTER 1 
INTRODUCTION 
Lowering total plasma cholesterol concentration has been shown to reduce 
coronary heart disease (CHD). Consuming natural dietary components may reduce 
plasma cholesterol (Lin et al., 2004; Graaf et al., 2002; Kerckhoffs et al., 2002.). FDA 
(2000) endorsed health claims show that food products containing adequate amounts of 
plant sterols/stanols may reduce CHD. Natural compounds such as phytosterol and 
oryzanol have been shown to have potent cholesterol-lowering effects in various animal 
and human studies (Graff et al., 2002; Hakala et al., 2002; Trautwein et al., 2002; Vissers 
et al., 2000; Rong et al., 1997; Kahlon et al., 1996.). Due to the minimal toxic side effects 
of these compounds in natural plant seeds, they may provide an alternative dietary 
supplement in place of existing pharmaceutical agents to improve serum cholesterol 
levels and thus reduce the risks of atherosclerosis and heart disease.  
 Rice bran oil (RBO) has been used in some Asian countries as cooking oil 
(Orthoefer, 1996; Rukmini and Raghuram, 1991). The oil is concentrated in the germ and 
bran layers, which are dispersed during rice milling (Orthoefer, 1996). Oil content in rice 
bran is about 20% (Orthoefer, 1996), containing ~ 43.8% oleic acid and ~ 39.3% linoleic 
acid, which is similar to the fatty acid profile of peanut oil (Edwards et al., 1994).  
 Rice bran oil contains relatively high unsaponifiable fractions (UF), such as plant 
sterols and stanols, γ-oryzanol, tocopherols and tocotrienols, compared to other common 
vegetable oils. Rice bran contains ~ 3000mg/kg γ-oryzanol and up to 300mg/kg vitamin 
E. These two compounds have been considered as potent antioxidants and may be 
bioactive in prevention of certain chronic diseases (Xu et al., 2001). Studies showing rice 
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bran oil lowering plasma cholesterol more effectively than other commonly used 
vegetable oils, suggest plant sterols, γ-oryzanol and tocotrienols may be the major active 
compounds responsible for this significant effect (Hakala et al., 2002; Qureshi et al., 
2001; Sugano and Tsuji, 1997; Rogers et al., 1993; Kahlon et al., 1992; Rukmini and 
Raghuram, 1991).  
γ-Oryzanol, was first extracted from rice bran oil as ferulate esters of plant sterols 
(Rogers et al., 1993). It has been purified and identified as having 10 components: 
cycloartenyl, 24-methylenecycloartanyl, campesteryl, ∆7-campestenyl, sitosteryl, ∆7-
sitostenyl, stigmasteryl, ∆7-stimasteryl, and sitostanyl and campestanyl ferulates (Xu and 
Godber, 1999). γ-Oryzanol was used to decrease plasma cholesterol, platelet aggregation, 
cholesterol absorption from cholesterol-enriched diets and aortic fatty streaks (Hakala et 
al., 2002). Other than the promising cholesterol-lowering effects, γ-oryzanol may have 
other pharmacological effects such as regulation of the estrous cycle, growth-accelerating 
action, and the ability to promote skin capillary circulation (Rong et al., 1997). Results 
from a number of animal and human studies (Vissers et al., 2000; Rong et al., 1997; 
Sugano and Tsuji, 1997; Hegsted et al., 1993; Yoshino et al., 1989.) have demonstrated 
the cholesterol-lowering benefits of RBO and/or γ-oryzanol.  
γ-Oryzanol is also a potential antioxidant as its chemical structure contains 
phenolic moiety (Hakala et al., 2002, Xu et al., 2001). In Xu et al. (2001)’s study, they 
demonstrated that γ-oryzanol might be a more important antioxidant in the reduction of 
cholesterol oxidation than vitamin E in rice bran. Using a cholesterol oxidation system, 
they found a 10-fold higher level of γ-oryzanol than vitamin E in rice bran and all the 
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components in γ-oryzanol exhibited significant antioxidant activity, with 24-
methylenecycloartanyl ferulate having the highest antioxidant activity.  
The similar structures of plant sterols and γ-oryzanol to that of cholesterol 
suggested that the similarity might be responsible for the hypocholesterolemic effects of 
RBO. These components might compete with the binding sites of cholesterol and inhibit 
cholesterol absorption in the intestine, causing greater amounts of cholesterol to be 
excreted and metabolized to bile acids in the feces (Vissers et al., 2000; Sugano and 
Tsuji, 1997; Rogers et al., 1993; Rukmini and Raghuram, 1991).      
Cholesterol is synthesized in virtually all cells in the body from acetyl-CoA. The 
capacity is greatest in the liver and the intestinal wall. These tissues supply over 90% of 
the endogenous plasma cholesterol, and the endogenous synthesis accounts for more than 
two thirds of the total cholesterol store. Cholesterol is delivered to the liver in the form of 
chylomicron remnants, as well as in the form of LDL-C and HDL-C. The disposal of 
cholesterol comes from reabsorbed cholesterol from the gut in the enterohepatic 
circulation and HDL. The liver disposes of cholesterol by excretion in bile as free 
cholesterol and after conversion to bile salts (Devlin, 1997). It is estimated that neutral 
sterol, most of which is cholesterol, represents about 55%, and bile acids 45% of total 
steroid excretion in the feces (Groff and Gropper, 1995). When the amount of dietary 
cholesterol is reduced, de novo biosynthesis of cholesterol in the liver and the intestine is 
increased to satisfy the needs of other tissues and organs, as well as to replace bile salts 
and cholesterol lost from the enterohepatic circulation in the feces (Devlin, 1997). 
The bile acids are the end products of cholesterol metabolism. Chemical analyses 
have identified two primary bile acids, cholic acid and chenodeoxycholic acid, which are 
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synthesized in the liver and derived from cholesterol (Uchida et al., 1984). The primary 
bile acids are composed of 24 carbon atoms, contain two or three OH groups, and have a 
side chain that ends in a carboxyl group (Devlin, 1997). The primary bile acids would be 
conjugated with taurine or glycine in the liver to form conjugated bile acids, which are 
excreted into the intestine where they are partially deconjugated and transformed into a 
series of secondary bile acids by bacterial fermentation (Grundy et al., 1965). Other 
minor amounts of bile acids include 17 secondary bile acids, such as deoxycholic acid 
and 3α, 12 α-dihydroxy-7-oxo-5- β-cholanic acid, etc., which are also synthesized from 
the actions of the gut flora on primary bile acids (Hawkins et al., 2002). Since bile acids 
can return to the liver during enterohepatic circulation, prevention of their returning to the 
liver would stimulate the conversion of cholesterol to bile acids and therefore its 
excretion. This might be the main hypothetical mechanism for the hypocholesterolemic 
effect (Rong et al., 1997; Sugano and Tsuji, 1997; Kahlon et al., 1996; Rukmini and 
Raghuram, 1991) of oryzanol in RBO.  However, the complex structures of bile acids 
make it very difficult to determine and identify each component (Grundy et al., 1965).       
This study investigated cholesterol-lowering effects of RBO by analysis of fecal 
cholesterol and bile acids, using a gas chromatography with flame ionization detector 
(GC-FID). However, some studies have suggested that various plant sterols might have 
more hypocholesterolemic effects than γ-oryzanol (Trautwein et al., 2002; Vissers et al., 
2000; Weststrate and Meijer, 1998). The control diet in this study contained corn oil, 
which has higher levels of linoleic acid than RBO. One of the objectives in this study was 
to investigate if γ-oryzanol is responsible, at least partially, for the cholesterol-lowering 
effects of RBO.  The other objective was to compare bioactivity of three different forms 
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of γ-oryzanol associated with its effects on fecal steroid excretion, compared with γ-
oryzanol recovery in the feces. It was hypothesized that RBO γ-oryzanol would have 
greater bioactivity than γ-oryzanol dissolved in corn oil, followed by crystalline γ-
oryzanol.  
This study was a continuation of the experiment of Gillespie (2003). The result 
showed that bioavailability of crystalline γ-oryzanol was lower relative to crystalline γ-
oryzanol dissolved in corn oil.  
Since the lipid profile of rice bran oil and peanut oil are similar (Rukmini and 
Raghuram, 1991), it might have been more appropriate to use peanut oil than corn oil, in 
order to minimize the differences of the component profile between oils in the control 
and the treatment groups. Also, a cholesterol-enriched diet would have been more likely 
to manifest potential hypocholesterolemic effects of rice bran oil, as γ-oryzanol might 
affect cholesterol metabolism by altering dietary cholesterol absorption (Rong et al., 
1997).
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CHAPTER 2 
LITERATURE REVIEW 
2.1 NUTRITIONAL PROFILE OF RBO 
 
Rice bran oil is concentrated in the germ and bran layers in rough rice grain. 
Crude rice bran oil contains ~96% of saponifiable fractions and ~ 4% unsaponifiable 
fractions, which include phytosterols, sterolesters, triterpene alcohols, hydrocarbons, and 
tocopherols (Table 1). Oryzanol content is about 2% in crude rice bran oil. These 
unsaponifiable fractions were reported to be bioactive and to have positive nutritional and 
health benefits (Orthoefer, 1996). 
The hypolipidemic effect of RBO was investigated in animal and human studies. 
Generally, these studies showed a positive cholesterol-lowering effect of RBO, although 
the results may vary due to factors such as subject models, endogenous cholesterol level 
in the body, concentration of active components in the diets, and duration of the diet 
treatment. These studies appeared to indicate the bioactive components of RBO act 
synergistically to induce hypocholesterolemic effects (Vissers et al., 2000; Sugano and 
Tsuji, 1997; Kahlon et al., 1992; Rukmini and Raghuram, 1991). 
Some researchers reported that supplements of rice bran were effective in 
lowering total cholesterol and LDL levels in human subjects with moderate 
hypercholesterolemia (Hundemer et al., 1991). However, serum cholesterol was found to 
be lowered when patients with mild hypercholesterolemia consumed 300 g/d of 
unpolished rice, or 100 g/d of stabilized rice bran, while consuming either 30g/d of rice 
bran for 6 weeks or 60 g/d of rice bran for 4 weeks were shown to be ineffective (Hakala 
et al., 2002).  
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Table 1. Composition of Crude Rice Bran Oil  
    
Component    % 
Saponifiable lipids    90-96 
 Neutral Lipids 88-89 
  Triglycerides 83-86 
  Diglycerides 3-4 
  Monoglycerides 6-7 
  Free fatty acids 2-4 
  Waxes 3-4 
 Glycolipids 6-7 
 Phospholipids 4-5 
    
Unsaponifiable lipids  4.2 
 Phytosterols 43 
 Sterolesters 10 
 Triterpene alcohols 28 
 Hydrocarbons 18 
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2.2 RICE BRAN OIL AND ITS EFFECTIVE COMPONENTS 
2.2.1 Fatty Acids 
 RBO has a nonspecific fatty acid profile among the vegetable oils. The amount of 
linoleic acid is rather moderate, and RBO also contains a relatively high proportion of 
oleic acid. The fatty acid composition of RBO is similar to that of peanut oil, thus many 
studies used peanut oil as a control (Table 2). One study with rats fed RBO diet 
demonstrated a significant reduction in total serum cholesterol, LDL-cholesterol, and an 
increase in fecal steroid excretion compared with the same concentration of peanut oil 
diet (Rukmini and Raghuram, 1991). Another study by Seetharamaiah and 
Chandrasekhara (1988) found that RBO lowered serum cholesterol levels in rats more 
than those fed with peanut oil, when cholesterol and cholic acid were incorporated into 
the experimental diets.  These results suggested that some minor components in RBO 
such as the unsaponifiable fraction may play a role in the hypocholesterolemic action 
(Rukmini and Raghuram, 1991). When a small portion of unsaponifiables from RBO was 
added to peanut oil diets of the rats, the cholesterol-lowering action was magnified (Ikeda 
et al., 1985).   
 Edwards and Radcliffe (1994) compared the effects on serum lipids in rats with 
RBO and corn oil (Table 3), which has higher linoleic acid than RBO. Their results 
suggested that these two vegetable oils had a similar effect on serum total cholesterol 
level, at least at the concentration of the oils they used; however, the effects on serum 
cholesterol level may vary when incorporated into atherogenic diets fed to rats for a 
period longer than 5 weeks. In Wilson et al. (2000)’s study, they fed RBO and corn oils 
as 20% of energy, respectively, to monkeys for four weeks. RBO produced similar 
 - 9 -






  Table 3. Fatty Acid Composition of Rice ran Oil and Corn Oil 
 
 
Fatty acid (%) Rice bran oil Corn oil 
C16:0 12.7 9.65 
C18:0 2.0 2.14 
C18:1 43.8 28.1 
C18:2 39.3 58.9 
C18:3 1.1 0.79 
C20:0 0.59 0.37 








Fatty acid (%) Rice bran oil Peanut oil 
C14:0 0.6 - 
C16:0 21.5 14.4 
C18:0 2.9 3.1 
C18:1 38.4 42.6 
C18:2 34.4 35.9 
C18:3 2.2 - 
C20:0 - 2.7 
C22:0 - 1 
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reductions in serum total cholesterol and LDL-C compared with corn oil, which has 
higher polyunsaturated fats and lower saturated fats. These researchers concluded that 
unsaponifiable fractions in RBO could compensate for its high saturated fats and thus UF 
played a predominant role in decreasing cholesterol levels without reducing serum HDL-
C compared with other vegetable oils. However, Nicolosi et al. (1991) found that RBO 
and corn oil were equally effective in reducing serum cholesterol level in monkeys.       
2.2.2 Unsaponifialbe Fractions (UF) 
Rice bran oil (RBO) has been observed and confirmed to have 
hypocholesterolemic effect in a variety of human and animal studies. It has a propensity 
for improving serum cholesterol levels and lipoprotein profiles compared with more 
commonly used vegetable oils. This may be due to its relatively high contents of 
unsaponifiable fractions (UF) than most common vegetable oils. Refined RBO may 
contain 1.5-2.6% of UF and crude RBO may contain up to 5% of UF, while most refined 
vegetable oils contain 0.3-0.9% of UF (Rong et al., 1997). UF is composed of various 
forms of plant sterols, triterpene alcohols, 4-methyl sterols, oryzanol, tocopherols and 
tocotrienols, and some less polar components. In a study by Nagao et al. (2001), the 
hypocholesterolemic effect of RBO was compared with a pure extract of UF and found to 
be similar in both. Thus, studies have suggested that UF in RBO may play a very 
important role in cholesterol-lowering activity (Nagao et al., 2001; Rong et al., 1997). As 
mentioned earlier, the lipid profiles are similar in RBO and peanut oil. A study suggested 
that unsaponifiable fractions might play a role in the cholesterol-lowering effects in RBO 
compared to the peanut oil control diet (Seetharamaiah and Chandrsekhara, 1988). 
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In Kahlon et al. (1996)’s study, they reported that unsaponifiables from RBO 
added to cellulose control diet tended to lower total plasma cholesterol levels, but the 
effect was not significant compared with the control diet. They suggested that intact rice 
bran might have synergistic cholesterol-lowering effects as other components act together 
with the unsaponifiable fractions (UF). They also reported that liver cholesterol decreased 
up to 3-fold with rice bran diets compared with the cellulose diets with equivalent levels 
of UF. However, rice bran diet with added UF had significantly higher fat excretion and 
significantly greater plasma and liver cholesterol reduction than other rice bran (without 
adding UF) diets, which may indicate UF plays a main role in lowering cholesterol levels. 
In addition, significant excretion of neutral sterol in feces was observed with intake of 
neutral sterol. Furthermore, fecal excretion of fats and neutral sterol were significantly 
negatively correlated with liver cholesterol, which suggested the possible mechanisms of 
hypocholesterolemic effects by UF through diminished absorption-reabsorption of 
cholesterol and lipid from the digestive tract and interference with cholesterol 
metabolism by sterols from UF in RBO.  
Nagao et al. (2001) concluded from their study that UF in RBO leads to a 
decreased serum cholesterol concentration by interrupting the absorption of intestinal 
cholesterol rather than by modifying VLDL-C, LDL-C and HDL-C in the liver, as an 
elevation of cholesterol excretion into feces was reported. However, a dietary effect on 
the fecal bile acid excretion was not found, which may be because bile salts were not 
added to the diet in their study.  
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2.2.2.1 Plant Sterols (Phytosterol) 
Campesterol, β-sitosterol and stigmasterol are the most abundant plant sterols 
found in edible vegetable oils (Figure1). Among these plant sterols, β-sitosterol has been 
recognized as the predominant component in the cholesterol-lowering action (Trautwein 
et al., 2002). It is generally assumed that plant sterols inhibited intestinal absorption of 
dietary and biliary cholesterol, because of the similarity between the structures of plant 
sterol and that of cholesterol. Some studies indicated that plant sterols contributed more 
hypocholesterolemic effects than unsaponifiable factions. In addition, some plant sterols 
may be more active than others (Wilson et al., 2000). Large doses of plant sterols may 
inhibit cholesterol absorption in humans by lowering serum cholesterol level (Vissers et 
al., 2000). In the study of Vissers et al. (2000), they compared the cholesterol-lowering 
actions of plant sterols from RBO with triterpene alcohols from peanut oil in 
normolipidemic volunteers.  The concentrates were added to margarine that had the same 
fatty acid composition, and the subjects consumed the sunflower oil as a control, peanut 
oil, and RBO margarines for 3 weeks each. Their results showed that RBO margarine 
decreased serum total cholesterol and LDL-C compared with the control margarine, but it 
did not affect HDL-C level. Whereas the peanut oil margarine did not affect serum total, 
LDL-, or HDL-cholesterol compared with the control margarine. These researchers 
suggested that the cholesterol-lowering effects may be due to the 4-desmethylsterols 
especially β-sitosterol, but not 4,4’-dimethylsterols such as cycloartenol. Another study 
of Weststrate and Meijer (1999) found no effects of concentrated RBO sterols in healthy 
normocholesterolaemic and mildly hypercholesterolaemic human subjects, 
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Figure 1. Chemical Structures of Cholesterol and Major Plant Sterols 
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which was in contrast to Vissers et al. (2000). Weststrate and Meijer (1999) found that 
sterol-esters mainly sitosterol, campesterol and stigmasterol from soybean oil was 
effective in lowering plasma total cholesterol and LDL-cholesterol levels without 
affecting HDL-cholesterol concentration. They suggested that the more similar structures 
of plant sterols to cholesterol may contribute more effective competition with cholesterol 
in the micelles.   
However, other researchers fed rats a combination of the 4,4’-dimethylsterol 
cycloartenol and the 4-desmethylsterol β-sitosterol, and found that the effect on 
cholesterol levels was similar to β-sitosterol alone. β-sitosterol was less absorbed and 
thus more effective in inhibiting cholesterol absorption (Ikeda et al., 1985). The lack of 
the effect of 4,4’-dimethylsterols could be that they may not displace intestinal 
cholesterol from the micelles due to the less comparable molecular structure of 
cholesterol (Kerckhoffs et al., 2002). 
On the other hand, Trautwein et al. (2002) suggested that the cholesterol-lowering 
effects of RBO might due to higher concentration of plant sterol (mostly in the form of β-
sitosterol) rather than dimethylsterols (found primarily in the oryzanol fraction). They 
also suggested that esterified sterols and stanols were equivalent in lowering total plasma 
cholesterol and LDL cholesterol by inhibiting cholesterol absorption and stimulating 
fecal cholesterol excretion, but did not affect bile acid excretion as cholesterol 7α-
hydroxylase activity did not differ. They fed to hamsters with a fat- or cholesterol-
enriched diet, combined with esterified 4-desmethylsterols from soybean oil, or esterified 
hydrogenated 4-desmethylsterols from the same source, or esterified 4,4’-dimethylsterols 
from oryzanol in RBO for 5 weeks. The results showed that both 4-desmethylsterols and 
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-stanols with 0.25% dose had equal effects and significantly (P<0.05) lowered serum total 
cholesterol (TC) by 15%. However, the effect of 4,4’-dimethylsterols at the optimal dose, 
which was 0.24%, lowered serum TC by 10%. The possible explanation might be the 
chemical structure similarity of these sterols to cholesterol, since 4,4’-dimethylsterols 
such as cycloartenol have two additional methyl groups at the site adjacent to the 
hydroxyl group (Trautwein et al., 2002). The daily fecal excretion of neutral sterols was 
significantly higher in sterol- and stanol- supplemented diets, but not in those fed with 
4,4’-dimethylsterols. Thus, Trautwein et al. (2002) suggested diminished intestinal 
cholesterol absorption may not be the primary mechanism of 4,4’-dimethylsterols in 
lowering serum TC in rats, but of sterols and stanols (Ikeda et al, 1985; Miettinen and 
Vanhanen, 1994; Vanhnen et al., 1994; Weststrate and Meijer, 1999). For fecal bile acid 
excretion, the hamsters fed 0.48% 4,4’-dimethylsterols had a significantly higher fecal 
output than the control diet group, but the results were not significant with either the 
sterol or the stanol group. This might indicate bile acid excretion as one of the primary 
mechanisms of cholesterol-lowering effects of 4,4’-dimethylsterols in RBO.  
Another study of Trautwein et al. (1997) compared different dietary fats on 
cholesterol profiles in hamsters. They found that rapeseed oil affected cholesterol 
metabolism by reducing cholesterol absorption, due to higher fecal output of cholesterol 
and bile acids in hamsters. Because the fatty acid profile is similar between rapeseed oil 
and olive oil, while rapeseed oil has more palmitic acid and 2.5 fold higher plant sterols, 
they attributed the greater hypocholesterolemic effects of rapeseed oil to its plant sterol 
concentration and/or the impact of saturated fats in rapeseed oil.     
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2.2.2.2 γ-Oryzanol              
 The most characteristic component of RBO is γ-oryzanol, which is a mixture of 
ferulic acid esters of triterpene alcohols and sterols in rice bran oil (Figure 2). 
Cycloartenol ferulate, 24-methylene cycloartanyl ferulate and campesteryl ferulate are the 
major components of γ-oryzanol (Xu and Godber, 1999). About 20% of unsaponifiable 
fraction in RBO is oryzanol (Rong et al., 1997). γ-Oryzanol may be used to inhibit tumor 
promotion, reduce serum cholesterol levels, and to treat nerve imbalance and disorders of 
menopause (Fang et al., 2003). 
The study by Seetharamaiah and Chandrasekhara (1989) was done to determine if 
oryzanol alone in RBO had hypocholesterolemic activity. The refined RBO, which 
contained traces of oryzanol, was used as one of the treatment diets, 0.5% oryzanol added 
to the same refined RBO was the other treatment, and peanut oil as a control diet. Their 
results in a cholesterol-enriched diet in rats showed that serum TC decreased 38% on the 
RBO diet and was further lowered by 20% with additional oryzanol when compared with 
the control. They concluded that the cholesterol-lowering effect of RBO was attributable 
to oryzanol as well as to other components in the RBO.        
A human study conducted by Yoshino et al. (1989) showed the long-term safety 
and significant hypolipidemic effects of oryzanol. The subjects with hyperlipidemia were 
treated with 300mg of γ-oryzanol for three months. The results showed that total 
triglycerides and LDL decreased significantly by the third month (P<0.05). The plausible 
explanation might be the inhibition of cholesterol absorption in the intestine. Also HDL 
was significantly elevated at the third month in all of the subjects, although the 
mechanism was not clear. The researchers suggested that γ-oryzanol would be a safe and 
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effective long-term agent to control plasma cholesterol levels in patients with mild 
hypercholesterolemia, although its effect proved relatively weaker than other 
hypolipidemic drugs.     
Rong et al. (1997) reported that oryzanol was an active ingredient responsible, at 
least partially, for the hypocholesterolemic activity of RBO. They found that non-HDL-C 
by 57% was reduced when adding 0.5% oryzanol to a diet containing coconut oil to 
hamsters for 10 weeks; although, increasing oryzanol to 1% and feeding hamsters with 
the diet for 7 weeks resulted in a 34% reduction in non-HDL-C. Further, aortic fatty 
streak formation was reduced 67% in both of the oryzanol-treated hamsters. However, 
both of the oryzanol treatments did not change de novo cholesterol synthesis as measured 
by HMG-CoA reductase activity. Also Rong et al. (1997) pointed out that the 
concentration of oryzanol in the first and second treatments were 8-fold and 4-fold 
higher, respectively, than the concentration in physically refined RBO.  On the other 
hand, the dietary cholesterol levels may modify the influence of oryzanol, as no 
significant effects on plasma lipids or lipoproteins were observed. It may suggest that 
oryzanol affected cholesterol metabolism by altering dietary cholesterol absorption. The 
study by Sharma and Rukmini (1987) reported that an increased excretion of fecal total 
sterol and total bile acids occurred when oryzanol was added to the diet fed to the mice. 
However, they could not elucidate the mechanisms of its hypocholesterolemic effects. In 
Sugano and Tsuji (1997)’s study, when rats were fed either cholesterol-enriched or 
cholesterol-free diets, the rats fed with RBO or RBO with additional oryzanol led to a 
significant decrease in cholesterol levels.  
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The similar structures of oryzanol to cholesterol suggests that oryzanol might 
compete for the binding sites with cholesterol, leading to more cholesterol and bile salt 
excretions in the feces. Also cycloartenol is a precursor of phytosterols and it may be 
absorbed and stored in the liver so it might compete with the binding sites of cholesterol 
in the liver, causing greater amounts of cholesterol and bile acid excretion (Rukmini and 
Raghuram, 1991).  
Another study reported by Kiribuchi et al. (1983) found that cycloartenol 
magnified the hypocholesterolemic effects of soy sterols in rats, probably through 
increasing fecal steroid excretion. Other researchers suggested that the structure of the 
sterols in γ-oryzanol might be less effective in lowering cholesterol absorption, as γ-
oryzanol was less effective than the fatty acid esters of plant sterols and stanols in 
lowering total cholesterol levels in some human studies (Weststrate and Meijer, 1998; 
Hakala et al., 2002).   
2.2.2.3 Tocopherols and Tocotrienols 
RBO is also a rich source of tocotrienols, and the content and biological activities 
are higher than those of tocopherols (Sugano and Tsuji, 1997; Qureshi et al., 2001). 
Tocotrienols differ from tocopherols in having three double bonds in the isoprene side 
chain. The subtle structural differences among tocotrienols are relative to the number and 
location of methyl groups on the chroman rings (Figure 3). The structural differences 
may influence their biological activities. δ-Tocotrienol is the most potent cholesterol 
inhibitor among the known tocotrienols, followed by γ-tocotrienol and α-tocotrienol 
(Qureshi et al., 1996a).  Also, tocotrienols differ substantially in their capacity to 
suppress tumor cell proliferation (Quershi et al., 2000). Their multitherapeutic properties,  
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such as hypocholesterolemic, antioxidant, antithrobotic, anticancer and anti-inflammatory 
have been reported in various animal and human studies (Quershi et al., 2001). Qureshi et 
al. (2000) isolated and identified two novel tocotrienols, d-P21-T3 (desmethyl tocotrienol) 
and d-P25-T3 (didesmethyl tocotrienol) from stabilized rice bran. Male chickens (6 week 
old) were fed a tocols-containing diet (except α-tocopherol and β-tocotrienol) for 24 days, 
and the results showed that the serum total and LDL-C were significantly (P<0.05) 
decreased by 13-31% and 17-78%, respectively, when compared to the control group. 
Among the tocotrienol-containing diets, the total and LDL-C levels were lowered in the 
following order: d-P25-T3 > d-P21-T3 > δ-T3 > γ-T3>α-T3. Similar effects were also 
observed in which these tocotrienols inhibited HMG-CoA reductase activity. The 
mechanism was considered to be by suppression of HMG-CoA reductase activity through 
a post-transcriptional mechanism (Parker et al., 1993). Among the known tocols, d-P25-
T3 exhibited the greatest cholesterol lowering activity in chickens, which may be due to 
its maximum inhibition of HMG-CoA reductase activity.  
Another study by Qureshi et al. (2001), looked at the effects of tocols, including 
two novel tocotrienols, d-P25-T3 and d-P21-T3, from rice bran on inhibition of 
atherosclerotic lesions in C57BL/6 ApoE-deficient mice. Their results showed that the 
mice fed for 14 weeks with a low fat diet supplemented with TRF25 (a mixture of tocols 
with high ratio of tocotrienol to tocopherol purified from rice bran) or d-P25-T3 decreased 
atherosclerotic leision size by 42% and 47% (P<0.01), respectively, whereas the α-
tocopherol supplemented diet had only 11% (P=0.62) reduction. It was suggested that 
tocotrienols had greater antioxidant activity to suppress cholesterol oxidation and 
melanoma cell proliferation than those of tocopherols.  
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2.3 POSSIBLE MECHANISMS OF CHOLESTEROL-LOWERING EFFECTS OF 
RBO 
 The cholesterol-lowering effects of RBO are probably attributable to its relatively 
high UF, which play a more important role than its fatty acids. Three major groups of UF 
are physiologically bioactive in improving cholesterol levels in animals and human 
subjects. These include plant sterol/stanol, γ-oryzanol and tocols (tocopherol and 
tocotrienol). These compounds work synergistically to exhibit hypocholesterolemic 
effects. The possible mechanisms for each group of compounds are summarized as 
follows.  
 Plant sterol-stanol: Several mechanisms of plant sterols effect on cholesterol 
concentration in the body may include: 1) formation of a nonabsorbable complex with 
cholesterol; 2) altering the size and/or stability of the micelles; 3) interferences with 
cholesterol esterification in the mucosal cell; 4) interacting with protein receptors which 
are required in cholesterol absorption (Rong et al., 1997).     
 γ-Oryzanol: In a review (Rukmini and Raghuram, 1991) of biochemical aspects of 
the hypolipidemic action of RBO, the hypothesized mechanisms by which oryzanol 
lowers cholesterol levels may include: 1) Oryzanol inhibits cholesterol absorption by 
interfering with its absorption, at least by the mode of luminal action, as well as, or 
instead of intracellular events that reflect long-term effects of a feeding regiment. 2) 
Oryzanol exercises its effects on cholesterol metabolism at sites other than the intestine. 
Studies suggested its hypocholesterolemic effects by reducing non-HDL lipid profiles but 
no such effect on HDL-C.     
 Tocols: Higher contents of tocotrienol than tocopherol in rice bran (Qureshi et al., 
2001; Qureshi et al., 2000; Rukmini and Raghuram, 1991) in which RBO has more 
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significant antioxidant properties. All the tocols share three features in an antioxidation 
system (Qureshi et al., 2000): 1) a hydrogen donor group, 2) an atom having at least one 
lone pair of electrons, and 3) a side chain comprising one or more isoprenoid-like units. 
Tocols exhibited significant antioxidant activity that inhibits cholesterol oxidation (Xu et 
al., 2001). The cholesterol-lowering activities by tocols include reducing serum TC and 
LDL-C by suppressing HMG-CoA reductase activity through a novel post-transcriptional 
mechanism (Qureshi et al., 2000). Tocotrienols may also reduce atherosclerotic lesion 
size while the mechanism was unknown (Qureshi et al., 2001).   
2.3.1 Antioxidant Activity of Oryzanol and Tocotrienols in RBO 
 Cholesterol oxidation products have been suggested as a major cause of heart 
disease. Reduction of cholesterol and LDL-C oxidation may contribute to the potential 
cholesterol-lowering property of RBO (Xu et al., 2001). Similar to lipid oxidation, 
cholesterol oxidation is initiated by free radicals to produce hydroperoxide, peroxide, and 
other oxidized products. In the study of Xu et al. (2001), using a cholesterol-oxidation 
system, three major γ-oryzanol components, which are 24-methylene cycloartanyl 
ferulate, cycloartenyl ferulate and campesteryl ferulate, showed significant antioxidant 
activity after 24 hours of oxidation, whereas oxidation products were not significantly 
lower in each treatment of tocols after 24 hours of oxidation. Also, the oxidation products 
in the treatment of γ-oryzanol were significantly lower than those of tocols. It was 
assumed that the greater antioxidant activity of γ-oryzanol than tocols might be due to the 
similarity between the structure of γ-oryzanol and that of cholesterol. Overall, the 
antioxidant activity of both γ-oryzanol and tocols contribute to the potential anti-
atherogenic effects of RBO.     
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2.4 FECAL STEROID EXCRETION RELATED TO CHOLESTEROL LEVEL 
The effect of RBO through fecal steroid excretion was considered as the mode of 
action of UF, specifically, the effect of plant sterols may be through fecal neutral sterol 
excretion. However, there have not been many investigations on cholesterol-lowering 
effects of RBO related to fecal steroid excretion (Figure 4), especially on human subjects. 
Kahlon et al. (1996) suggested that the cholesterol-lowering activity in RBO was 
probably through increasing excretion of fat and neutral sterol as they found that the 
hamsters fed UF diet or UF added to rice bran oil had significantly higher fat excretion. 
However, their results for fecal neutral sterol excretion did not negatively correlate with 
plasma cholesterol, while the fecal fat excretion did. Sharma and Rukmini (1986) 
reported increased fecal excretion of both neutral sterols and bile acids in rats when fed 
RBO compared with those fed peanut oil.  
2.4.1 Studies of Functional Foods Related to Fecal Steroid Excretion and 
Cholesterol-lowering Effects 
 
An increased excretion of fecal neutral sterol and bile acids increases the 
conversion of excess cholesterol to bile acids in the enterohepatic circulation.     
Preliminary studies showed that the effects of certain components in plant foods (such as 
pectin, oat bran, etc.) on lowering serum cholesterol levels could be due to secretion of 
bile acids and neutral sterol in the feces (Garcia-diez et al., 1996). 
Neutral sterol includes cholesterol, coprostanol, cholestanol and coprostanone 
(Lin et al., 2004). In fecal neutral sterol (Figure 5), coprostanol is a metabolite of 
cholesterol, formed by the action of gut microflora through fermentation. Bile acids 
converted from cholesterol in the enterohepatic circulation exist as 24 carbon units and  
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Figure 5. Chemical Structures of Major Neutral Sterols. 
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include cholic acid, chenodeoxycholic acid, and their bacterial metabolites, deoxycholic 
acid and lithocholic acid (Batta et al., 1984). 
Differences in cholesterol absorption were confirmed by measurement of neutral 
sterol levels in feces, and then the decrease in absorption of cholesterol was accompanied 
by the increase in the synthesis of cholesterol by the liver.  In the study of Hawkins et al. 
(2002), they reported that neutral sterol accounted for about 2% of fecal lipids. 
Cholesterol may represent about 70% of the total fecal neutral sterols, followed by 
coprostanol, but cholestanone would account for just 1-2% of total neutral sterol excreted 
(Trautwein et al., 1997, 1999). 
The synthesis of bile acids provides a direct means of converting cholesterol into 
bile acid (Figure 6) that facilitates the direct secretion of endogenous and exogenous 
cholesterol from the liver. The proportion of primary and secondary bile acids may 
depend on 7α-hydroxylase activity and/or primary bile acid availability (Cheung, 1998). 
 The study of Hawkins (2002) suggested that cholic acid was an in vivo mediator 
of negative feedback regulation of bile acid biosynthesis by the recruitment of different 
co-regulators to a target gene following activation by a ligand.  The study of Vahouny et 
al. (1987) was concerned with effects of fiber supplements on fecal bile acids and neutral 
sterols. They concluded that consistent results were observed in all of the insoluble fiber 
sources with increased fecal neutral sterols and more fecal cholic acids and a marked 
drop in hydrodeoxycholate levels. Their results suggested that primary bile acids 
represent a greater percentage of fecal bile acids, indicating reduced metabolism by 
colonic bacteria. However, their data on fecal excretions of sterol outputs did not appear 
to correlate directly with the observed effects of the fiber supplements on plasma  
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cholesterol levels in the rats. They concluded that the fiber-induced changes in fecal bile 
acid content, concentration or composition, might not be the sole mechanism involved in 
lowering of serum cholesterol levels. 
In the study of Uchida (1984), they found that dietary cholesterol was 
preferentially converted to chenodeoxycholic acid, although the precise mechanism is not 
fully understood. It is widely accepted that the phytosterols form non-absorbable 
complexes with cholesterol, and bile acids play an essential role in cholesterol absorption. 
In addition, they also suggested that bile acids derived from chenodeoxycholic acid 
decreased more than that derived from cholic acid.  
The study of Nakamura et al. (2000) on the effects of rutin on hyperlipidemic rats 
suggested that fecal bile acid excretion increased significantly only in the rats 
administered with a certain amount of rutin, while there were no significant changes in 
cholic acid and chenodeoxycholic acid or in the ratio of primary bile acids. Another study 
on fecal steroid excretion in rat by oral administration of gymnemic acids found similar 
results as cholesterol-lowering effects were dose dependent and they found that fecal 
excretion of cholesterol and cholic acid derived bile acids had a positive correlation with 
gymnemic acids (Nakamura et al., 1999). However, some studies showed that 
deoxycholic acid was the most abundant bile acid excreted in the stool of the mice 
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2.5 LIPID METABOLISM IN OVARIECTOMIZED RATS 
Ovariectomized (OVX) rats have been found to have higher cholesterol levels 
than normal rats due to the deficiency of estrogen (Junqueira et al., 2002). OVX 
increased body energy store and susceptibility of non-HDL-C to oxidation (El-Swety et 
al., 2002).  The deficiency of estrogen appears to be responsible for the effects since 
estrogen replacement prevents the extra energy gain. Thus, the energy flux is 
accompanied by adaptation of lipid metabolism, such as increased hepatic lipid 
production and elevated circulation level of lipoproteins. However, OVX did not alter 
liver cholesterol content (Picard et al., 2000). Picard et al. (2000) tested the ability of 
EM-652.HCl, an estrogen antagonist to prevent obesity and abnormality of lipid 
metabolism. The study showed that EM-652.HCl could prevent most of the abnormalities 
of energy and lipid metabolism in the OVX rats treated with the EM-652.HCl. agent. 
Nogowski et al. (1998) studied the effect of genistein on lipid metabolism in OVX rats. 
They concluded genistein strongly inhibited lipogenesis in the liver and adipocytes of 
OVX rats, while cholesterol metabolism seemed to have unexpected results.  
 However, some bioactive components in vegetable oils such as RBO and corn oil 
have hypolipidemic effects and also RBO was used to treat disorders of menopause (Fang 
et al., 2003). Thus, it is of interest to determine the differences in fecal steroid excretion 
between OVX rats and sham operated rats, although they were treated with corn oil in the 
control groups. 
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3.1 ANIMAL MODELS 
A total of 47 nine-month old Sprague Dawley retired female breeder rats were  
purchased from Harlan Sprangue Dawley, Inc. (Indianapolis, IN) and served as the 
animal models in this study. They were individually housed in suspended wire-mesh-
bottomed cages in a controlled environment (temperature controlled, 12-hour light/dark 
cycle). The rats were blocked by weight and then randomly assigned to a diet group. 
Twenty rats were used as controls with half ovariectomized (OVX) two weeks prior to 
the experiment while the others underwent a sham surgery; the remaining 27 rats were 
ovariectomized (Colona, 2002) as well, and equally divided among three dietary 
treatments (Gillespie, 2003). 
3.2 DIETS 
The diets (Table 4) (Gillespie, 2003) were a modification of the formula based on 
the AIN-93 M maintenance diet, which may have a better balance of essential nutrients 
for adult rodents (Reeves et al., 1993). All of the animals were sustained for 11 weeks on 
a cholesterol-free diet that was either a control group diet or treatment diets with 2.8g/kg 
of oryzanol. Tocopherol stripped corn oil was used in the control group and two of the 
treatment groups, and RBO was used in the other treatment group. They were grouped as 
follows:  
(C & SH) - Control diets (n=20): Corn oil;  
(CO) - 2.8 g/kg of crystalline oryzanol (n=9): Corn oil; 
(DO) – 2.8 g/kg of crystalline oryzanol dissolved in corn oil (n=9): Corn oil; 
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(RO) - 7% oryzanol rice bran oil (n=9): RBO. 
 
 
Table 4. Diet Formula. 
Ingredient (g/kg diet) C & SH CO DO RO 
Casein 150 150 150 150 
Sucrose 100 100 100 100 
Cornstarch 455.7 455.7 455.7 455.7 
Dextrinized cornstarch 155 155 155 155 
Corn oil, stripped 40 40 40 0 
Rice bran oil 0 0 0 40 
Cellulosec 50 50 50 50 
Mineral Mix AIN-93 M 35 35 35 35 
Vitamin Mix AIN-93M 10 10 10 10 
Choline bitartrate 15 15 15 15 
L-cystine 1.8 1.8 1.8 1.8 
Oryzanol 0 2.8 2.8b 2.8a 
  
a. 2.8 g of Oryzanol was originally contained in the high- oryzanol rice bran oil. 
b. Oryzanol added and dissolved in the tocopherols stripped corn oil.   




The 2.8g/kg of oryzanol supplementation was to allow for an equal amount of 
oryzanol in all the treatment diets, based on the 7% oryzanol concentration in the high 
oryzanol rice bran oil. The RBO used in the study was donated by Riceland, Inc. 
(Stuttgart, AR). Corn oil stripped of tocopherols was purchased from Dyets, Inc. 
(Bethlehem, PA), and crystalline oryzanol was purchased from Samlong Chemical Co., 
LTD. (Changxin, Jiangsu, China). For the DO group, crystalline oryzanol was completely 
dissolved in the corn oil portion before adding the solution to the diet mix. Whereas for 
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CO group, the crystalline oryzanol was added directly to the diet mix. Diets were stored 
in airtight containers at -20oC.  
3.3 COLLECTION AND PREPARATION OF FECES  
Foods were replenished three times each week. At weeks 6 and 10, referred to as 
period A and B, respectively, each animal was placed in an individual metabolism cage 
for 24 hours according to a random schedule to collect feces. Fecal samples were 
collected in plastic containers and frozen until analyzed.  
Frozen fecal specimens were allowed to thaw at room temperature. Feces from 
each animal was transferred to individual glass jars and dried in a VWR 1410 vacuum 
oven (West Chester, PA) at 60oC under –15 in. Hg pressure. After dehydration, each fecal 
sample was ground and kept in a capped glass container in a Dry-Keeper desiccator 
cabinet by Bel-Art Products (Pequannock, NJ) for storage. Steroid extracts from a 0.25 g 
portion of each fecal sample were analyzed using Gas Chromatography Flame Ionization 
Detector (GC-FID) as detailed in a later section.        
3.4 EXTRACTION OF FECAL STEROIDS   
The extraction procedures were patterned after Cheung (1998), Vahouny et al. 
(1987) and Evrard and Janssen (1968) with some modifications. An aliquot of 0.25g of 
each fecal sample was weighed into a clean 15-mL test tube, then 0.2mL of 50ppm stock 
solution of α-cholestane (ICN Biomedicals Inc. Aurora, OH) dissolved in hexane was 
added as an internal standard for cholesterol, along with 0.1mL of 100ppm stock solution 
of β-cholanic acid (ICN Biomedicals Inc. Aurora, OH) in hexane as an internal standard 
for bile acids. After vigorous vortexing for 30 seconds, the mixture was transferred to a 
50-mL 24/40 stoppered test tube, which connected to a circulating condenser system. 
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After acid-digesting with 4mL of acetic acid at 110oC for 60 minutes and cooling, 5mL of 
toluene (Mallinckrodt, Paris, KN) and 1mL of distilled water were added to the sample. 
As toluene and acetic acid are miscible, 1 mL of distilled water was added to separate the 
organic solvent extract. The liquid mixture then was transferred to a plastic 40-mL 
centrifuge tube, capped and vortexed using a Type 37600 Mixer (Thermolyne 
Corporation, Dubuque, IW). After centrifuging at 1,500xg for 4 minutes at 22oC in a 
Hermle Z383K centrifuge (Labnet International, In. Woodbride, NJ), the supernatant of 
acetic acid-toluene extract was transferred using a Pasteur pipette to a clean 40-mL test 
tube. This procedure was repeated three times. The toluene-lipid extract was then 
completely evaporated using a CentriVap Console vacuum (Labconco, Kansas City, MO) 
at 98oC for 60 minutes, without coldtrap. The lipids were then subjected to enzymatic 
hydrolysis to the bile acid conjugates with 12 units of stock solution choloylglycine 
hydrolase (Sigma Chemical, St. Louis, MO) by adjusting the mixture to the optimized pH 
at 5.6, using a 410 A pH Meter (Orion Research Inc. Boston, MA). Two mL of 0.2N 
pH5.6 sodium acetate buffer solution (Appendix A) and 1 mL of 1.85% EDTA (Sigma 
Chemical, St. Louis, MO) solution were added to the dried lipids. After vortexing and 
measuring the pH, 1 mL of choloylglycine hydrolase solution was added and the pH was 
measured again. The mixture was adjusted to pH5.6 by adding ~3-4 mL of the sodium 
acetate buffer and then incubated in a water bath at 37oC for 5 minutes.  
3.4.1. Fecal Neutral Sterol Extraction and Analysis 
The deconjugated lipids were saponified with alcoholic potassium hydroxide 
(AOCS, 1988) by adding a drop of 80% KOH (w/v) with a Pasteur pipette, and then 
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adding 37.5µL of absolute ethanol USP. The mixture then was vortexed for 30 seconds 
and incubated in a water bath at 45oC for 30 minutes.  
After cooling, cholesterol (including oryzanol) was extracted with 5mL of 
Petroleum ether (Fisher, Fairlawn, NJ) and the extraction was repeated three times. After 
the mixture was transferred to a 40mL centrifuge tube, capped, vortexed, and centrifuged 
in the Hermle Z383K centrifuge, using the same condition as mentioned earlier. After 
that, the organic solvent was allowed to separate into two layers. The petroleum 
supernatant was transferred with a Pasteur pipette to a clean 15-mL test tube and then all 
extracts were combined and dried completely using the CentriVap Console vacuum at 
65oC for 55 minutes.  
The neutral sterol, after evaporation, was light-yellow color. After cooling,  
0.2mL of hexane was added and vigorously vortexed for one minute. The liquid was 
carefully transferred to a 2mL vial (Supelco, Rena, Nevada) for GC and capped. One µL 
of the hexane-sterol extract was injected with a syringe (Varian, Walnut, Creek, CA) into 
a CP-3800 Gas Chromatography Flame Ionization Detector with a SACTM-5 Capillary 
Column (Supelco). This type of capillary column does not require TMS derivatization 
and is able to separate sterols (SupelcoTM Column Test Report). The operating condition 
used was as follows:  an injection port temperature of 300oC with 100:1 split ratio; the 
column oven temperature was 270oC that was held for 18 minutes; the detector 
temperature was 200oC. Helium was used as a carrier gas at a flow rate of 2 mL/min.  
3.4.2. Fecal Bile Acid Extraction and Analysis 
The residue in the 40mL centrifuge tube after extraction of sterols contained most  
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of the bile acids. The residue was acidified with concentrated HCl by adding ~ 9 drops 
with a Pasteur pipette then was adjusted to pH 1 using the pH measuring tip. After 
vigorous vortexing, the color of the content was dark yellow. Anhydrous diethyl ether 
(Fisher, Fairland Malinckrodt, Paris, KN) was used as the solvent to extract total bile 
acids. Again, the mixture was capped and vigorously vortexed before centrifugation in 
the Hermle Z383K centrifuge. The operating condition of the centrifuge was as described 
previously. Extraction was repeated three times and the supernatant of the diethyl ether-
bile acid extracts were combined and evaporated using the CentriVap Console vacuum at 
60oC for 45 minutes. After cooling, the bile acid extract was methylated (Appendix B) 
with 2mL of BCl3-methanol (Supelco, Bellefonte, PA) and 1mL of 2, 2-dimethoxy-
propane (Sigma, St. Louis, MO). The mixture was vortexed for 2 minutes and incubated 
in a 65oC water bath for 10 minutes.  Two mL of hexane and 1mL of distilled water was 
added after cooling. The mixture was vigorously vortexed and centrifuged for 2 minutes 
using a Physicians Compact Centrifuge (Clay Adams, Parsippany, NJ) to allow the two 
layers to separate upon standing. The upper hexane layer was very carefully transferred 
with a Pasteur pipette to a clean 15-mL test tube containing anhydrous Na2SO4 to absorb 
the excess water from the organic layer. After vortexing and centrifugation with the 
Physicians Compact Centrifuge, the clear hexane-bile acid extract was transferred to a 2-
mL GC vial (5896A, Hewlett Packard), capped and put into the autosampler. The 
operating conditions were:  an injection port temperature of 250oC; initial oven 
temperature was 42oC and maintained for 2 minutes, then increased at 4.0 degrees per 
minute to 222oC and maintained for 6 minutes. The column was a SupelcoTM2380 
Capillary Column (Supelco). Helium was used as a carrier gas at a flow rate of 2 mL/min.  
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3.5 OPTIMIZATION OF ANALYTICAL CONDITIONS  
To determine the major components for neutral sterol and bile acids, we used 
some standards to do the trials before developing the method for analysis. For 
cholesterol and oryzanol, 100ppm stock solution of α-cholestane dissolved in hexane and 
100ppm stock solution of cholesterol standard (ICN Biomedicals Inc. Aurora, OH) were 
first analyzed to determine the retention time. One µL of 100ppm α-cholestane, or 
100ppm cholesterol standard, or mixture of both, was injected into the CP-3800 GC-FID 
with the SACTM-5 Capillary Column (Supelco). The operating conditions were set as 
described in section 3.4.1. The peaks of α-cholestane and cholesterol appeared at the 
retention time of ~5.77 min. and ~9.45 min., respectively.  
 For bile acids, 100ppm stock solution with cholic acid standard (ICN  
Biomedicals Inc. Aurora, OH), or chenodeoxycholic acid standard (ICN Biomedicals Inc. 
Aurora, OH), or deoxycholic acid standard (ICN Biomedicals Inc. Aurora, OH), or total 
bile acid standard (ICN Biomedicals Inc. Aurora, OH) were performed using the same 
procedure as that described for bile acid extraction. The peaks of β-cholanic acid 
appeared at 2.83 min., cholic acid at 6.7 min., chenodeoxycholic acid at 11.53 min., 
deoxycholic acid at 34.0 min., and lithocholic at 37.0 min. Primary bile acids represented 
the total of cholic acid and chenodeoxycholic acid. Secondary bile acids represented the 
total of deoxycholic acid and lithocholic acid. Total bile acids represented the total of 
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3.6 FECAL ORYZANOL RECOVERY 
Since the chemical structure of oryzanol (esters of ferulic acid and sterols) is 
similar to that of cholesterol, oryzanol was extracted into sterols during cholesterol 
extraction. To determine this, we used purified crystalline oryzanol with the same 
extraction procedure as was used for cholesterol. Oryzanol was separated into three major 
compounds, which were most likely cycloartenol ferulate, 24-methylene cycloartanyl 
ferulate and campesteryl ferulate, as they are the major components of γ-oryzanol (Xu 
and Godber, 1999). The peaks appeared in the chromatogram at 11.7 min., 14.3 min., and 
17.0 min. The results of oryzanol were depicted as these three major components.  
3.7 GEL FORMING 
During fecal lipid or steroid extraction, the solution must be separated 
immediately upon centrifuging. If the solution does not separate immediately upon 
centrifuging, it forms a gel, which makes it difficult for extraction. Because of the large 
amount of soaps in the aqueous phase, gel formation occurred, in which case gentle 
warming or addition of 20% NaCl solution was used to solve the problem (Evrard and 
Janssen, 1968). 
3.8 STATISTICAL ANALYSIS 
Statistical Analysis System (SAS) version 9.0 (SAS Institute, Cary, NC, USA) 
was utilized for all statistical analysis. One-way analysis of variance (ANOVA) was used 
to compare the differences of data among the group means. Paired t-test was used to 
compare the differences of the two fecal collecting periods (A & B) in cholesterol, 
oryzanol and bile acid excretion within the diet group means. LSD test was used to 
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determine specific differences among the means. All data represent MEANS ± SEM; 
p≤0.05 was considered significantly different.
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CHAPTER 4 
 
RESULTS AND DISCUSSION 
 
4.1 COMPARISON OF DIFFERENCES BETWEEN TWO FECAL 
COLLECTION PERIODS  
 A paired t-test was used to compare feces collected in periods A and B of each 
animal for cholesterol excretion, fecal oryzanol excretion, cholic acid (CA), 
chenodeoxycholic acid (CDCA), primary bile acids (PBA), deoxycholic acid (DCA), 
lithocholic acid (LCA), secondary bile acids (SBA), and bile acids total (BAT). Total 
sample sizes were ninety-four with forty-seven for each period.  
Results (Table 5) showed that there was no significant difference  (P>0.05) in the 
data between period A and period B within each diet group; as such the following results 
were presented as the combined data from two periods. Feed intake in period B was 
significantly less in all diet groups when compared to that in period A, but weight gain 
was more efficient in period B (Gillespie 2003).  Gillespie’s (2003) results showed that 
significant differences of fecal oryzanol excretion existed in the individual data between 
period A and B in the CO group, but no statistically significant differences were found in 
individual data in the DO and RO groups between the two periods in her study. However, 
the methods of analysis used in the two studies were different, which may have affected 
the results.  
4.2 CHOLESTEROL EXCRETION 
RO group showed significantly greater cholesterol excretion than other diet 
groups (Table 6). Specific comparison of cholesterol excretion among the treatment 
groups also showed that RO group had significantly higher cholesterol excretion than the 
average of the other treatment groups (P<0.001). 
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Table 5. Comparison of Fecal Steroids between Collection Periods of A and B1, 2,3 
 Group CHOL4 ORY5 CA6 CDCA7 PBA8 DCA9 LCA10 SBA11 BAT12  
C (A) 
Mean 1.349 - 0.109 0.110 0.219 0.410 0.188 0.598 0.817 
SEM 0.237 - 0.024 0.032 0.047 0.187 0.031 0.240 0.247 
C (B) 
Mean 1.173 - 0.101 0.050 0.151 0.206 0.322 0.528 0.679 
SEM 0.122 - 0.049 0.037 0.088 0.095 0.102 0.300 0.313 
A vs. B NS NS NS NS NS NS NS NS NS 
SH (A) 
Mean 1.640 - 0.087 0.042 0.129 0.195 0.095 0.290 0.419 
SEM 0.276 - 0.039 0.011 0.035 0.127 0.044 0.142 0.184 
SH (B) 
Mean 1.447 - 0.045 0.032 0.077 0.107 0.087 0.194 0.271 
SEM 0.233 - 0.012 0.009 0.033 0.005 0.007 0.013 0.031 
A vs. B NS NS NS NS NS NS NS NS NS 
CO (A) 
Mean 1.565 3.958 5.117 3.196 9.513 12.688 7.724 20.412 29.925 
SEM 0.218 0.337 0.952 0.741 1.985 4.159 2.132 5.880 3.196 
CO (B) 
Mean 2.303 3.530 5.563 3.336 7.701 14.376 6.422 20.798 30.595 
SEM 0.166 0.857 0.802 0.524 1.755 3.529 1.737 3.756 3.191 
A vs. B NS NS NS NS NS NS NS NS NS 
DO (A) 
Mean 1.599 3.043 2.546 1.719 4.265 9.358 10.215 19.573 23.838 
SEM 0.201 0.619 0.855 0.455 1.013 3.413 3.212 2.954 3.234 
DO (B) 
Mean 1.631 3.077 1.488 1.471 2.949 7.712 9.165 16.877 19.826 
SEM 0.287 0.543 0.211 0.575 0.274 2.070 1.049 4.450 5.564 
A vs. B NS NS NS NS NS NS NS NS NS 
NO (A) 
Mean 2.459 7.251 8.247 7.572 15.819 15.291 12.819 28.110 43.929 
SEM 0.471 0.305 2.405 4.420 4.033 2.750 1.480 4.587 7.767 
NO (B) 
Mean 3.162 8.670 10.229 4.910 15.139 15.721 8.087 23.808 38.947 
SEM 0.431 0.473 1.594 1.016 2.371 1.926 1.733 4.820 5.673 
A vs. B NS NS NS NS NS NS NS NS NS 
1Values are presented as peak area (PA) ratios to two internal standards accordingly. 
2Letter A or B follows the diet group name in parentheses represents collection period A 
or B, respectively.  
3NS implies a non-significant result (P>0.05). 
4 Cholesterol. 
5 Oryzanol. 
6 Cholic acid. 
7 Chenodeoxycholic acid. 
8 Primary bile acids. 
9 Chenodeoxycholic acid. 
10 Lithocholic acid. 
11 Secondary bile acids. 
12 Bile acids (total). 
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Table 6. Effects of the Diets on Fecal Cholesterol Excretion1, 2, 3   
 
1Values are presented as peak area (PA) ratio of cholesterol to α-cholestane (internal 
standard). 
2Sample size used in each group follows the diet group name in parentheses. 




The effect may be caused by oryzanol or possibly other components of UF in RBO 
(Seetharamaiah and Chandrasekhara, 1989). In Seetharamaiah and Chandrasekhara 
(1989)’s study, additional oryzanol was added to RBO and the results showed that serum 
total cholesterol level was lowered. However, they concluded that the 
hypocholesterolemic effect of RBO was not due to oryzanol alone. Furthermore, the 
differences among CO, DO, and SH groups were not significant (P>0.05), and there were 
no statistical significant differences among DO, SH and C groups either.   
The lack of a significant difference between the sham and the CO and DO diets 
may be due to hypocholesterolemic effects of the corn oil.  Typical corn oil contains 
1.18% β-sitosterol (Rukmini and Raghuram 1991), which has been recognized as the 
predominant component in the cholesterol lowering action (Trautwein et al., 2002), 
although the corn oil used in this study was stripped of tocopherol that may have also 
impacted phytosterol levels. Ikeda et al. (1985) reported that combining the 4,4’- 
dimethylsterol cycloartenol (one of the major components in oryzanol) and 4-
desmethylsterol (β-sitosterol) in diets fed to rats showed that the effects on decreased 
cholesterol levels were similar to β-sitosterol by itself. If this was the case in this study, it 
    Diet Group C (10) SH (10) CO (8) DO (9) RO (8) 
    Mean 1.261 C 1.544 B,C 1.934 B 1.615 B,C 2.811 A 
    SEM  0.101  0.145  0.164  0.222  0.118 
  RO vs. AVE (CO & DO)    P<0.001         
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might explain why there was no significant difference in fecal cholesterol excretion 
among those corn oil diet groups.  
Although it was hypothesized that oryzanol in oil form would be more bioactive 
and thus induce more fecal steroid excretion than the crystalline form, the CO group 
showed significantly higher cholesterol excretion than the C group. Thus, the results 
found in this study did not support this hypothesis. Interestingly, Vissers et al. (2000) 
suggested that the effect of sterols in rice bran oil on serum lipoprotein in humans might 
be due to plant sterols, but not oryzanol.  If plant sterol did play a major role, it might 
also explain the similar effects on fecal cholesterol among the corn oil diet groups. 
However, CO and DO treatment groups contained extremely high concentration of 
oryzanol (2.8g in 40 g in corn oil), thus it was assumed that DO would show more 
significant cholesterol lowering effects as well. No published studies compared the 
crystalline form and dissolved oil form of oryzanol. Thus, this comparison requires more 
study to determine relative bioactivities of different forms of oryzanol.  
4.3 FECAL ORYZANOL EXCRETION AMONG THE TREATMENT GROUPS 
RO produced significantly higher oryzanol excretion (P<0.05) than the other 
treatment groups (Table 7), followed by CO and DO groups.  The oryzanol that is not 
recovered from the feces would indirectly reflect that which was absorbed plus that 
which was changed by the digestive process into a form that was not detectable.  It is 
known that plant sterols and oryzanol are poorly absorbed in the small intestine (Ling et 
al., 1995; Fujiwara et al., 1983). Gillespie (2003) found that the CO group had 
significantly higher oryzanol excretion than RO and DO groups, and similar levels of 
oryzanol was excreted between RO and DO groups. Oryzanol absorption was not 
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measured in this study, so the difference in absorption among the treatment groups could 
not be determined directly, but it appears that in all treatment diets, a fairly substantial 
portion of the ingested oryzanol is changed into a form that is not detectable. 
The fact that there was no difference between CO and DO groups indicated that 
the change in oryzanol during digestion was not significantly different between the 
dissolved oil form of oryzanol and the crystalline form. 
 
Table 7. Fecal Oryzanol Excretion among Three Treatment Groups1, 2, 3 
  Diet Group CO (8) DO (9) RO (8) 
  Mean 3.744 B 2.914 B 7.956 A 
  SEM 0.439 0.484 0.777 
  RO vs. AVE (CO & DO)* P=0.004   
 
1Values are arbitrary and presented as peak area (PA) ratio of oryzanol to α-cholestane 
(internal standard). 
2Sample size used in each group follows the diet group name in parentheses. 
3Values within a row with the same letter of superscript are not significantly different 
(P>0.05). 
 * Significant effects of test treatment diets on different bile acid excretion. NS implies a 
non-significant result (P>0.05). 
 
 
However, Gillespie (2003) found that the dissolved oil form of oryzanol had lower fecal 
recovery than the crystalline form.  A possible explanation could be the analytical 
methods were very different in the two studies. The HPLC analysis of oryzanol used by 
Gillespie (2003) may more accurately measure total oryzanol than using GC-FID. Ten 
components of oryzanol have been identified using HPLC (Xu and Godber, 1999), but 
only three components were detected using the GC-FID method. Certain components 
might be more predominantly detected in HPLC.  Also, differences in extraction and 
 - 45 -
sample preparation between the two studies may have contributed to the divergent 
results.  
 It is logical that bioavailability of oryzanol in RBO would be higher than the 
dissolved form of crystalline oryzanol in corn oil, since compatibility of oryzanol in RBO 
should be higher than in corn oil. However, this study showed a significantly higher fecal 
oryzanol excretion in the RO group than the other treatment groups.  Perhaps, more intact 
forms of oryzanol were excreted in the feces in the RO group that were more readily 
detected by the GC-FID method, and thus it appeared that more oryzanol was excreted in 
the feces. 
The metabolism of oryzanol has not yet been elucidated very clearly. Fujiwara et 
al. (1983) reported that 9.8% of the 14C-labeled γ-oryzanol was excreted as major urinary 
metabolites such as ferulic acid, dihydroferulic acid, m-hydroxyphenylpropionic acid, m-
coumaric acid, m-hydroxyhippuric acid and hippuric acid. Of the administered γ-
oryzanol, 10-20% was metabolized to yield ferulic acid in the small intestine and 84.5% 
was excreted in the feces, thus possibly as much as 64.5% of intact γ-oryzanol would be 
excreted in the feces; however, an extremely low percentage (0.3%) was absorbed in the 
lymphatic ducts. Fujiwara et al. (1983) concluded that oral intake of oryzanol was mainly 
absorbed in the blood via the portal vein. This might be the explanation for why more 
oryzanol was detected in the feces in CO group than in DO group, because crystalline 
oryzanol might be excreted in much more intact forms than the dissolved oil form. 
If the data for cholesterol excretion is associated with oryzanol excretion, these 
findings indicate that fecal cholesterol excretion might not necessarily relate negatively to 
fecal oryzanol excretion, at least based on the results found in this study. This could be 
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explained through the relatively higher level of UF in RBO and their synergistic 
activities. Nagao et al. (2001) suggested that fecal cholesterol excretion was significantly 
higher in RBO and RBO simulated oil plus UF than RBO simulated oil, which indicated 
that UF played an important role in fecal cholesterol excretion. An appreciable amount of 
UF in RBO, including oryzanol and other plant sterols, may interfere with intestinal 
cholesterol absorption to a greater extent than oryzanol by itself. Another concern was if 
the cholesterol-free diet in this study would produce fecal steroid excretion by the effects 
of RBO or oryzanol. Sharma and Rukmini (1986) reported a significant neutral sterol 
excretion was found in rats fed a cholesterol-free diet compared to the control peanut oil 
diet. An extremely high concentration of oryzanol used in this study might magnify 
cholesterol-lowering effects of oryzanol in either RBO or corn oil.   
4.4 FECAL BILE ACID EXCRETION 
4.4.1 Primary Bile Acids 
 All of the treatment groups except DO showed a significantly higher CA 
excretion than the control groups (P<0.05). The results of CA excretion (Table 8) 
suggested that oryzanol may play a more important role in bile acid excretion. Among the 
treatment groups the highest excretion was found in the RO group, where it was 
significantly higher than CO and DO groups; also, a significant difference was found 
between CO and DO groups (P<0.05). The specific comparison of the effects among the 
three treatment groups showed that RO had significantly greater effects on CA excretion 
than the average of the other two treatment groups (P<0.001). The results may indicate 
that the RO group, which also contained high concentration of UF had a significantly 
higher fecal bile acid excretion than the other two treatment groups because oryzanol 
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might be more bioactive in RBO than in corn oil. The significant difference between CO 
and DO groups was unexpected, but may reflect differences in oryzanol digestibility as 
previously described.   
   
Table 8. Effects of the Diets on Fecal Primary Bile Acid Excretion1,2,3 
    Bile acids C (7) SH (8) CO (7) DO (8) RO (7) 
    CA4 0.105C 0.066C 5.34B 2.012C 9.238A 
    SEM 0.052 0.020 0.873 0.532 2.145 
    RO vs. AVE (CO & DO)* P<0.001     
    CDCA5 0.08C 0.037C 3.266B 1.595B 6.241A 
    SEM 0.026 0.013 0.656 0.447 1.137 
    RO vs. AVE (CO & DO)* P<0.0001     
    PBA6 0.185C 0.103C 8.607B 3.607C 15.479A 
    SEM 0.077 0.031 1.473 0.898 3.191 
    RO vs. AVE (CO & DO)* P=0.0001     
1Values are arbitrary and presented as peak area (PA) ratio of bile acids to β-cholanic 
acid (internal standard). 
2Sample size used in each group follows the diet group name in parentheses. 
3Values within a row with the same letter of superscript are not significantly different 
(P>0.05). 
4 Cholic acid. 
5 Chenodeoxycholic acid. 
6 Primary bile acids. 
* Significant effects of test treatment diets on different bile acid excretion. NS implies a 
non-significant result (P>0.05). 
 
 
Fecal CDCA excretion (Table 8) showed that all of the treatment groups had 
significantly higher excretion than the control groups. Again RO had the greatest CDCA 
excretion among the groups, which was also significantly higher than the average 
excretion of CO and DO groups (P<0.0001). No significant difference in CDCA 
excretion was noted between CO and DO groups. The significant differences (P<0.05) 
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between the treatment groups and the control groups supported the possibility that 
oryzanol may play a major role in fecal bile acid excretion. 
4.4.2 Secondary Bile Acids  
 DCA excretion (Table 9) was found to be the highest in the RO group among the 
five diet groups, and it was significantly higher in the RO group than the average of CO 
and DO groups (P=0.0003). All of the treatment groups showed a significantly greater 
DCA excretion than the control groups (P<0.05). These results also supported the 
possibility that oryzanol promoted fecal bile acid excretion. 
 
Table 9. Effects of the Diets on Fecal Secondary Bile Acid Excretion1,2,3 
    Bile acids C (7) SH (8) CO (8) DO (8) RO (8) 
    DCA4 0.308C 0.151C 13.532A,B 8.535B 15.506A 
    SEM 0.101 0.057 3.089 3.275 2.347 
    RO vs. AVE (CO & DO)* P=0.0003     
    LCA5 0.255B 0.090B 7.073A 9.690A 10.453A 
    SEM 0.125 0.034 1.597 4.193 1.784 
    RO vs. AVE (CO & DO)* P=0.01     
    SBA6 0.563B 0.241B 20.605A 18.225A 25.959A 
    SEM 0.177 0.091 4.637 6.755 4.110 
    RO vs. AVE (CO & DO)* P=0.0023     
1Values are arbitrary and presented as peak area (PA) ratio of bile acids to β-cholanic 
acid (internal standard). 
2Sample size used in each group follows the diet group name in parentheses. 
3Values within a row with the same letter of superscript are not significantly different 
(P>0.05). 
4 Deoxycholic acid. 
5 Lithocholic acid. 
6 Secondary bile acids. 





 For LCA excretion (Table 9), all of the treatment groups showed significantly 
higher LCA excretion than the control groups. RO exhibited the highest excretion among 
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the diet groups, but the differences among the treatment groups were not significant 
(P>0.05); although, again, excretion for RO was significantly greater than the average of 
the other two treatment groups (P=0.01). Thus, the effect of oryzanol was exhibited in 
LCA excretion as well. 
4.4.3 Total Bile Acids  
 Total bile acids (BAT) (Table 10) were the results for the combined primary bile 
acids (PBA) and secondary bile acids (SBA). The BAT excretion from highest to lowest 
was RO>CO>DO>C>SH. All of the treatment groups showed a significantly higher 
excretion of BAT than the control groups, which indicated that hypocholesterolemic 
effects of oryzanol might promote bile acid synthesis and/or excretion. Although RO 
showed the highest BAT excretion among the five diet groups, the difference was not 
statistically significant from that of CO. Differences of BAT excretion were not 
statistically significant between CO and DO groups either. However, RO exhibited 
statistically greater fecal bile acid excretion than the average of the other two treatment 
groups (P<0.0001).  
 Among the treatment groups, CA excretion was higher than CDCA excretion 
(Figure 7), and DCA excretion was higher than LCA excretion (except for the DO group) 
(Figure 8). These findings might indicate that a high dose of oryzanol increased cholic 
acid-derived bile acid excretion. However, DCA excretion was higher than CA excretion, 
and SBA excretion was higher than PBA excretion, which might indicate that oryzanol 
could cause fermentation in the colon, as conversion of primary bile acids to secondary 
bile acids generally occurs due to fermentation by the bacteria in the colon. The 
unexpected results for LCA excretion with DO, in which there was a higher excretion 
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than that of CO, could be an anomaly because the CO group showed a higher fecal 
steroid excretion in all the results except LCA excretion. 
 
Table 10. Effects of the Diets on Fecal Total Bile Acid Excretion (BAT)1,2,3 
    Bile acids C (7) SH (8) CO (8) DO (8) RO (8) 
    BAT4 0.748C 0.344C 29.212A,B 21.832B 41.438A 
    SEM 0.203 0.115 5.256 6.496 6.089 
    RO vs. AVE (CO & DO)*     P<0.0001     
1Values are arbitrary and presented as peak area (PA) ratio of bile acids to β-cholanic 
acid (internal standard). 
2Sample size used in each group follows the diet group name in parentheses. 
3Values within a row with the same letter of superscript are not significantly different 
(P>0.05). 
4 Bile acids (total). 





 Few published papers studied cholesterol-lowering effects of oryzanol or RBO on 
fecal bile acid excretion. Although Sharma and Rukmini (1986) pointed out that RBO 
had significant effects on fecal bile acid excretion when compared with the peanut oil 
control diet, they did not specifically study excretion of individual neutral sterol or 
individual bile acids. Thus, it makes it hard to compare the results and effects of RBO or 
oryzanol through fecal steroid excretion in this study with other published studies.  
 RO and CO groups showed a significantly higher primary bile acid excretion than 
DO and the control groups. The bioactivity among oryzanol in three different forms 
appeared to be in the order of RO>CO>DO, although its bioavailability was not 
necessarily related to its bioactivity when considering its activity on fecal bile acid 
excretion. Heinemann et al. (1988) indicated that the relationship between absorbability 
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of plant sterols and their ability to inhibit cholesterol absorption was inversed. If that was 
true, it would be possible that oryzanol may have a similar effect as plant sterols because 

























1Bars show mean ± SEM. 
2PA Ratio represents peak area ratio of bile acids to β-cholanic acid (internal standard). 
 





Also it may explain partially why RO had the most γ-oryzanol recovered in the feces 
while it also caused the most fecal bile acid output. Similarly, CO (the crystalline form of 
oryzanol) had more oryzanol recovered than DO (dissolved oil form of crystalline 
oryzanol), and also caused more fecal bile acid output.  
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4.5 FECAL CHOLESTEROL VERSUS FECAL BILE ACIDS  
 When comparing fecal cholesterol excretion with fecal bile acids among the five 
diet groups, it was apparent that fecal cholesterol excretion was greater than fecal bile 
acid excretion in the control groups. However, among the treatment groups that contained 






















1Bars show mean ± SEM. 
2PA Ratio represents peak area ratio of bile acids to β-cholanic acid (internal standard). 
  





cholesterol excretion. The explanation could be that corn oil appeared to be more 
responsible for inhibition of intestinal cholesterol absorption by enhancing fecal 
cholesterol excretion, and oryzanol may be more responsible for fecal bile acid excretion 
but also inhibits cholesterol absorption. Studies by Rukmini and Raghuram (1991) and 
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Trautwein et al. (2002) supported this point as well, as they reported that 4,4’- 
dimethylsterols (mostly in oryzanol) might play a major role in fecal bile acid excretion. 
4.6 OVARECTOMIZED RATS AND SHAM OPERATED RATS IN THE 
CONTROL GROUPS 
 
 Ovarectomized (OVX) rats and intact rats (sham operated) were used in the 
control groups. OVX rats may have higher levels of cholesterol in the body due to the 
deficiency of estrogen (Junqueira et al., 2002), thus the fecal excretion was supposed to 
be higher than the sham rats under the same feeding condition. A general appraisal of the 
data for fecal steroid excretion between C and SH groups fed control diet indicates that 
the SH group had a higher cholesterol excretion than C group, while C group had a 
higher bile acid excretion than SH group; although these differences were not statistically 
significant (P>0.05). No fecal oryzanol was detected in either of the control groups. 
These results suggested that the control diet used in this study had no effect on 
cholesterol absorption and bile acid enterohepatic circulation between the OVX and the 
intact rats, thus they could be regarded as similar experimental animals in this study.  
4.7 FECAL BILE ACID EXTRACTION METHODS AND DETERMINATION 
 To simplify the results of fecal bile acids, deconjugation of bile acid conjugates 
was performed, thus the data in this study reflected free bile acid without the amide bonds 
to glycine or taurine, although a test to determine complete deconjugation was not done 
in this experiment.  Batta et al. (1984) reported that choloylglycine hydrolase did not 
hydrolyze the taurine conjugate of cholic acid. As such, the inability of choloylglycine 
hydrolase to hydrolyze all the substrates might underestimate total bile acids present. 
They also suggested that choloylglycine hydrolase activity was greatly reduced when the 
conjugate of keto-cholic acid was the substrate. The specificity of the enzyme was toward 
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chenodeoxycholic acid and cholic acid conjugated with amino acids other than glycine 
and taurine. In addition, the enzyme activity was affected by the elongation of the side 
chain and hydroxyl groups in the bile acids. Their findings may indicate the prudence of 
using other methods to deconjugate bile acids in order to obtain a more accurate 
measurement of total bile acids. 
 Assays used to determine bile acids might affect the results differently as bile 
acids have extremely complex and diverse forms. Some studies reported the extraction of 
bile acids after deconjugation by choloylglycine hydrolase and then analysis by GC-FID 
after acidification and methylation, using 5β-cholanic acid or 23-nordeoxycholic acid as 
internal standard. Other than determination of basic bile acids, ketonic derivatives were 
converted by chromic acid oxidation, and standards, including different forms of 
conjugated and deconjugated bile acids, as well as reference ketonic esters, were used as 
reference standards (Nakamura, et al., 2000, Grundy et al., 1965). Some other studies 
used an enzymatic method to determine fecal bile acids by using 3α-hydroxy steroid 
dehydrogenase (Sheltawy and Josowsky, 1975). However, these methods were either too 
complex or too briefly described for incorporation into the analysis in this experiment.             
Results of different studies on fecal bile acids varied as well. Some studies 
reported that dihydroxy bile acids such as chenodeoxycholic acid and lithocholic acid 
might have increased fecal excretion under acidic pH conditions (Trautwein et al., 1998 
and 1999). Vlahcevic et al. (1991) suggested that chenodeoxycholic acid might be more 
effective in terms of feedback inhibition of bile acid synthesis than cholic acid. It might 
be because less chenodeoxycholic acid and more cholic acid returned to the liver, which 
might stimulate cholesterol 7α-hydroxylase activity and possibly up-regulate bile acid 
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synthesis (Chiang and Stroup, 1994; Trautwein et al., 1999). However, other studies 
reported that increased cholic acid excretion was found in rats fed gymnemic acids, 
suggesting the compound might interfere with cholesterol absorption and bile acid 
reabsorption (Nakamura et al., 1999). Other studies on the effects of dietary fiber on fecal 
steroid excretion suggested that a higher cholic acid proportion of the fecal total bile 
acids might be due to the compounds being bound to cholic acid stronger than 
chenodeoxycholic acid (Vahouny et al., 1987; Cheung, 1998). 
However, no published paper has studied whether oryzanol or RBO reflect their 
hypocholesterolemic effect through fecal bile acid excretion or only mention total bile 
acid excretion (Seetharamaiah and Chandrasekhara, 1989) as a possible mechanism. The 
results found in this study showed that oryzanol might increase fecal deoxycholic acid or 
secondary bile acids more predominately than primary bile acids, due to fermentation in 
the colon. Also, the results of fecal bile acid excretion supported the possibility that 
oryzanol may lower cholesterol levels through fecal bile acid excretion as the primary 
mechanism. More study may be needed to investigate the extent of oryzanol effects on 
specific bile acids.  
4.8 CHOLESTEROL-LOWERING EFFECTS OF ORYZANOL AND 
PHYTOSTEROL  
 
 The main difference of the diets between the non-RBO treatment groups (CO and 
DO) and the control groups (SH and C) was the addition of oryzanol in CO and DO. 
When comparing the fecal steroid excretion between the control groups to the non-RBO 
treatment groups, the higher fecal steroid excretion in the two treatment groups indicated 
a significant hypocholesterolemic activity of oryzanol, at least at the concentration in this 
study. The significantly greater fecal bile acid excretion in CO and DO groups than SH 
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and C groups, as well as no significant differences in fecal cholesterol excretion among 
CO, DO and SH or DO, C, and SH groups might indicate the major mechanism of 
oryzanol in lowering cholesterol levels is through interference in bile acid reabsorption in 
the enterohepatic circulation, whereas plant sterol may interfere with cholesterol 
absorption, mainly. The results in this study supported that of Kiribuchi et al. (1983), who 
reported that cycloartenol and probably 24-methylenecycloartanol, the two major 
components in oryzanol, attributed cholesterol-lowering effects by increasing fecal 
excretion of acidic steroids. On the other hand, phytosterol has a more similar structure to 
cholesterol than oryzanol does. The results for fecal cholesterol excretion in this study 
could indicate that phytosterol has a more pronounced ability to displace cholesterol in 
the micelles, and thus interfere with cholesterol absorption. A sterol structure with a 
cyclopentane ring might be a minimum requirement for inhibiting cholesterol absorption 
in the intestine (Vissers et al. 2000). From Fujiwara et al. (1983)’s study, the absorption 
route of oryzanol appeared to be different from that of cholesterol and phytosterol, whose 
absorption rates were reported as ~50% and ~5%, respectively (Ling and Jones, 1995). 
Phytosterol along with cholesterol were incorporated into micelles via lymphatic ducts 
and absorbed in the small intestine. As the gut poorly absorbs phytosterol, about 95% of 
dietary phytosterol enters the colon and is excreted in the feces. A major mechanism of 
inhibition of cholesterol absorption by phytosterol is generally proposed as reduced 
cholesterol content in the micelles. Since phytosterol is more hydrophobic than 
cholesterol, they may displace cholesterol from micelles thus restricting solubility of 
synthesis and excretion by metabolizing enzymes in the colon. However, the influence of 
phytosterol on conversion of cholesterol into bile acids was not consistent in different 
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studies (Ling and Jones, 1995). These studies did support the possibility that both 
oryzanol and phytosterol were poorly absorbed in the body.      
4.9 EFFECTS OF RICE BRAN OIL AND CORN OIL 
Some studies reported that the cholesterol-lowering effects between RBO and 
corn oil were similar (de Deckere and Kover, 1996; Lichtenstein et al., 1994). In 
Lichtenstein et al (1994)’s study, they reported that RBO resulted in plasma lipid and 
apolipoprotein concentrations that were similar to other commonly used vegetable oils. 
However, these studies did not add other potential components to RBO to manifest the 
effects. Cholesterol-lowering effects might not be appreciable in conventionally used 
refined rice bran oil, due to the low concentration of oryzanol (51mg per 100g oil) (de 
Deckere and Kover, 1996). However, RBO used in this study had an extremely high 
concentration of oryzanol (2.8 g in 40 g oil), which might be the reason for cholesterol-
lowering effects of RBO and/or oryzanol that were clearly manifested when compared to 
the control diets. Among the treatment groups, the fact that RO exhibited significantly 
higher fecal steroid excretion than CO and DO groups may suggest that the potent 
hypocholesterolemic effect of RBO is attributable to other components in the UF in 
addition to oryzanol, as RBO contains a relatively higher level of UF than corn oil.  Also, 
a higher content of UF in RBO compared with corn oil, which has similar 
hypocholesterolemic effects (Kahlon et al., 1992), may be the reason for the cholesterol-
lowering capabilities of RBO that were not explained by its fatty acid composition 
(Nicolosi et al., 1991). Another study by Kahlon et al. (1996) suggested that UF in RBO 
promoted fecal neutral sterol excretion probably by diminished absorption-reabsorption 
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of cholesterol. The results in this study also supported this point, as plant sterols and 
oryzanol in RBO promoted fecal cholesterol and bile acid excretion, respectively.   
4.10 LIMITATIONS OF THIS STUDY 
Results in this study were presented as peak area (PA) ratios of cholesterol and 
bile acids to the internal standards of α-cholestane and β-cholanic acid, respectively. The 
reason was that both neutral sterol and bile acids are complex compounds of different 
components, which are cholesterol metabolites with chemical structure similar to 
cholesterol. Cholesterol accounts for more than 70% of the total neutral sterol fraction 
(Trautwein et al., 1997); other neutral sterols such as coprostanol are metabolites of 
cholesterol, formed by the action of gut microflora (Cheung, 1998). As mentioned earlier, 
when the amount of dietary cholesterol is reduced, de novo biosynthesis of cholesterol in 
the liver and the intestine is increased to satisfy the needs of other tissues and organs, as 
well as to replace bile salts and cholesterol lost from the enterohepatic circulation in the 
feces (Devlin, 1997). Some studies suggested that the amount of cholesterol in fecal 
neutral sterol excretion might be partly due to the plant compounds added. Less 
cholesterol and more coprostanol would probably be excreted as increased microbial 
breakdown of cholesterol in the large intestine occurs due to the ingestion of plant 
compounds (Trautwein et al., 1999).     
Bile acids are a more complex mixture of different bile acid compounds as 
mentioned previously. Primary bile acids are the major components, and more than a 
dozen different forms of secondary bile acids are derivatives of primary bile acids formed 
by intestinal bacteria (Hawkins et al., 2002). In the liver, both primary and secondary bile 
acids bind to either glycine or taurine to form conjugated bile acids. However, during the 
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process of bile acid metabolism, different secondary bile acid derivatives, as well as 
ketonic derivatives, would be formed. Because of a lack of standards for all of these 
components, this study focused on four major primary and secondary bile acids, to 
compare cholesterol-lowering effects of oryzanol and RBO reflected by PA ratio of the 
major compounds in fecal steroids to the internal standards. As such, the actual amount of 
fecal steroid excretion caused by oryzanol or rice bran oil intake was not elucidated in 
this study. However, this study showed that rice bran oil and its unique compound, 
oryzanol, promoted fecal cholesterol and bile acid excretion, which might be a major 
mechanism for its hypocholesterolemic effects.  
Another concern was that the animals were not fed an atherogenic diet, which 
might affect the findings. Based on the literature review, most of the studies concerning 
cholesterol-lowering effects of certain bioactive components used high-fat, or high-
cholesterol, or dietary neutral sterol/bile acid to magnify the effects. Rong et al. (1994) 
suggested that rice bran oil might exhibit its hypocholesterolemic effects by decreasing 
plasma LDL-C through inhibition of dietary cholesterol absorption. Sharma and Rukmini 
(1986) also suggested that fecal steroid excretion was greater when feeding a high 
cholesterol diet on a RBO study. Thus, a cholesterol or fat-enriched diet may be required 
to observe the specific effects of certain levels of RBO or oryzanol on serum cholesterol 
level changes through direct or indirect methods.  
Also of concern is the lipid profile difference between RBO and corn oil.  Peanut 
oil, which has a more similar fatty acid profile to RBO, instead of corn oil as the control 
diet, may have been more appropriate for the study of the hypocholesterolemic effects of 
RBO (Sharma and Rukmini, 1986). However, this study could serve as a preliminary 
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study on the cholesterol-lowering effects of RBO and oryzanol through fecal steroid 
excretion. 
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CHAPTER 5 
SUMMARY AND CONCLUSION 
 RO group showed the greatest fecal cholesterol and bile acid excretion among the 
diet groups in this study and the differences were statistically significant (P<0.05).  In 
addition, fecal cholesterol and total bile acid excretion in RO was significantly higher 
than the average of the CO and DO groups (P<0.001). On the other hand, RO group 
showed a significantly higher oryzanol excretion than both of the other treatment groups 
(P<0.05). These findings indicated that the potential hypocholesterolemic effects of RBO 
with oryzanol were higher than corn oil with oryzanol. The cholesterol-lowering activity 
in the RO group may be due to synergistic effects of the components in UF, in addition to 
oryzanol, through the interference of cholesterol absorption and bile acid reabsorption to 
enhance fecal steroid excretion. However, oryzanol in RBO may be more bioactive than 
that in corn oil, even though the fecal recovery of oryzanol was shown to be the highest 
from RO in this study. Further study is needed to determine the correlation of cholesterol-
lowering effects to the oryzanol recovery rate from RBO. 
 The results between the CO and DO group showed that fecal cholesterol and total 
bile acid excretion were higher in the CO group than in the DO group, which might 
indicate that the crystalline form of oryzanol could have a greater cholesterol-lowering 
effect than the dissolved oil form of oryzanol, as the crystalline form might be less 
absorbed. However, the differences in the data between the CO and DO groups were not 
statistically significant (P>0.05). Further study needs to be done to elucidate whether the 
crystalline form or the dissolved oil form exhibits a greater potential in cholesterol-
lowering effects. 
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 Results from oryzanol in corn oil (CO and DO) and corn oil by itself (SH and C) 
established that significantly greater fecal bile acid excretion occurred with the oryzanol 
diets than the control diets, but a non-significant difference in fecal cholesterol excretion 
occurred between them. It might indicate the primary mechanism of oryzanol in lowering 
cholesterol levels may be through interference in bile acid reabsorption in the 
enterohepatic circulation. 
 It was also noticed that the effect through fecal cholesterol excretion was higher 
than fecal bile acid excretion in the two control groups, which may suggest corn oil 
appeared to be more responsible for inhibition of intestinal cholesterol absorption by 
enhancing fecal cholesterol excretion. 
5.1 FUTURE STUDY: 
It is suggested that the results of this study could be reaffirmed and/or clarified by 
employing the following actions in future studies: 
- Using peanut oil instead of corn oil as a control diet because it is more similar 
to rice bran oil in fatty acid composition. 
- Using high-fat or high-cholesterol diets, which may magnify the 
hypocholesterolemic effects of RBO. 
- Using GC-MS and HPLC analysis to obtain a more accurate quantification 
and determination of fecal neutral sterol and bile acids. 
- Evaluating the correlation between bioavailability of oryzanol and its 
hypocholesterolemic effects using crystalline and dissolved oryzanol forms or 
crystalline oryzanol added to rice bran oil instead of corn oil.  
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- Establish the correlation of fecal steroid excretion with serum and liver 
cholesterol changes.
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APPENDIX A 
0.25 M SODIUM ACETATE BUFFER (PH5.6) SOLUTION. 
Weigh 2.05 g anhydrous sodium acetate in a clean vial, and dissolve into 80 mL 
distilled water. Use a Pasture pipette to add acetic acid to adjust pH to 5.6 exactly, 
measured by a 410A pH Meter. Dilute to 100 mL with distilled water (M.W. of 
anhydrous sodium acetate is 82g/mol. 2.05/82=0.025M. 0.025M/100mL=0.25M). The 
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APPENDIX B 
REACTION AND MECHANISM: BCL3-METHANOL, 12% W/W. 
- Procedure:  
For either acid dissolve in nonpolar organic solvent, or evaporated to dryness, add 
2 mL BCl3-methanol and a water scavenger (such as 2,2-dimethoxypropane). (Water can 
prevent the reaction from going to completion, producing low yields). Heat at 60oC for 5-
10 minutes. After cooling, add 1 mL water and 1 mL hexane. Shake the reaction vessel – 
it is critical to get the esters into the nonpolar solvent. Carefully remove the organic layer, 
and dry it over anhydrous sodium sulfate.  
- Mechanism:   
       
Esterfication:    
Acid (BCl3) 
R-COOH + CH3OH------------------  R-COO-CH3 + H2O 
  
Transesterification: 
    Acid (BCl3) 
R-COOR’ + CH3OH------------------  R-COO-CH3 + R’OH 
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